Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: Am Heart J. 2010 Sep;160(3):428–434. doi: 10.1016/j.ahj.2010.06.009

Figure 2.

Figure 2

Change in left-ventricular end-diastolic volume (LVEDV) and end-systolic volume (LVESV) by cardiac MRI between baseline, 3 and 6 months following bone marrow mononuclear cell (BMC) administration or placebo administration. BMC administration was associated with a significant improvement in LVEDV compared to the placebo group (p < 0.01)